BDX

Business profile & competitive position

Becton, Dickinson and Company (BDX) is a global medical-technology company in the Healthcare sector, classified under the Medical - Instruments & Supplies industry. BD develops, manufactures and sells medical supplies, devices, laboratory equipment and diagnostic products for healthcare institutions, physicians, clinical laboratories, life-science researchers, pharmaceutical companies and the general public. As of September 30, 2025, the company operated through three worldwide segments: BD Medical, BD Life Sciences and BD Interventional. Its customer solutions span medication management, patient safety, infection prevention, surgical and interventional procedures, drug delivery, anesthesiology, infectious-disease and cancer diagnostics, and cellular research.

The financial footprint of that franchise is mixed. Net margin is 4.5% and return on equity is 3.8%, which are not the numbers normally associated with wide-moat, capital-light pricing power. Those low profitability metrics are more consistent with a capital-intensive manufacturer with broad, recurring-revenue product lines, heavy regulatory compliance and recent portfolio restructuring. Still, BD has delivered stable demand and is likely helped by high customer switching costs in regulated medical supplies; every one of the last eight reported quarters has beaten consensus earnings.

Financial posture

BDX’s current market capitalization is $50.9 billion. The stock trades at a P/E ratio of 55.6, supported by a net margin of 4.5% and an ROE of 3.8%, with a beta of 0.26. The latest closing price was $184.74, above the 50-day exponential moving average of $173.62, and the RSI stood at 57.5.

The valuation multiple is high relative to the company’s reported margin and return figures. That gap can be read as the market attaching a defensive premium to low-beta healthcare exposure and to a track record of reliable quarterly execution, but it also leaves the stock vulnerable to any reset in growth assumptions or integration setbacks. The 0.26 beta also fits the industry: medical-instrument and supply companies typically move less dramatically than the broad market because demand is tied to clinical utilization rather than discretionary cycles.

Strategic priorities & outlook

BD’s most recent 10-K lays out a clear near-term agenda built around restructuring, portfolio reshaping and a major transaction with Waters Corporation.

• Segment reorganization: Effective October 1, 2025, BD moved from three segments to five separately managed segments — Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences.
• Waters Reverse Morris Trust combination: BD is pursuing a Reverse Morris Trust combination of its Biosciences and Diagnostic Solutions business with Waters Corporation. The deal is expected to close around the end of the first calendar quarter of 2026. BD expects to receive approximately $4 billion in cash, and its shareholders are projected to own roughly 39.2% of the combined company after the transaction.
• Edwards Critical Care acquisition: In September 2024, BD completed the $3.914 billion acquisition of Edwards Lifesciences’ Critical Care product group, integrating it as BD Advanced Patient Monitoring within BD Medical.
• International footprint: BD manufactures in 18 countries outside the United States across EMEA, Greater Asia, Latin America and Canada.
• Divestitures: BD spun off its Diabetes Care business as Embecta Corp. in April 2022 and sold the Interventional segment’s Surgical Instrumentation platform in August 2023, booking a pre-tax gain of about $268 million on the latter sale.

The filing also flags foreign economic conditions and exchange-rate fluctuations as factors that have caused profitability on foreign revenues to fluctuate more than domestic profitability, with some non-U.S. business carrying greater risk.

Macro & geopolitical exposure

As a Medical - Instruments & Supplies company with global manufacturing and sales, BD faces the standard macro sensitivities of the sector. Regulatory approval and compliance in major jurisdictions — FDA clearances in the U.S., CE/MDR pathways in Europe, and similar regimes elsewhere — can dictate product launch timing and lifecycle economics. Reimbursement policy and hospital capital budgets influence demand for devices and disposables. Currency exposure is real: with operations in 18 non-U.S. countries, a stronger dollar can compress translated earnings, and the company explicitly notes that foreign profitability has historically been more volatile.

Beyond regulation and FX, trade policy matters for medical-device manufacturers. Tariffs on imported components or finished devices can affect cost structures, and supply-chain disruptions — whether from geopolitical events, raw-material availability or shipping constraints — can pressure margins. Input costs such as plastics, metals, electronics and specialized chemicals are also relevant. Finally, the industry is structurally tied to demographics: aging populations and rising chronic-disease prevalence support long-term demand, while healthcare-spending pressures in both public and private systems can act as a counterweight.

Recent developments

On September 2, 2026, GuruFocus published a DCF analysis headlining an intrinsic value estimate of $157 versus a then-price of about $187. On August 31, 2026, 247wallst.com included Becton Dickinson in a piece on healthcare stocks that have continued raising dividends through two recessions. That same day, 247wallst.com also ran a separate commodities-focused article quoting Jim Cramer on a mining stock. On August 27, 2026, BD issued a press release highlighting continued clinical innovation in advanced tissue regeneration. The GuruFocus valuation spread and the dividend-stability narrative both underscore the same tension: a business with durable demand but also a valuation multiple that assumes a lot of future execution.

Earnings behavior & post-earnings drift

BDX has beaten earnings estimates in all of the last eight reported quarters, a 100% beat rate, with an average earnings surprise of 8.2%. Across those quarters, the average 5-day price move after the report has been +3.66%, classified as an upward post-earnings drift. The next scheduled report is November 5, 2026, before the market open, with the current consensus EPS estimate at $4.06.

The last four quarters illustrate that beats do not always produce immediate gains:

• August 6, 2026: EPS of $3.23 vs. $3.14 estimate (2.9% surprise); the stock fell 0.12% the next day but rose 2.77% over the following five sessions.
• May 7, 2026: EPS of $2.90 vs. $2.78 estimate (4.3% surprise); the stock dropped 2.5% the next day and declined 5.74% over the next five sessions.
• February 9, 2026: EPS of $2.91 vs. $2.21 estimate (31.7% surprise); the stock jumped 5.3% the next day and climbed 8.8% over the next five sessions.
• November 6, 2025: EPS of $3.96 vs. $3.92 estimate (1.0% surprise); the stock rose 0.25% the next day and gained 8.82% over the next five sessions.

The overall upward drift suggests that, on average, the market has gradually repriced earnings beats higher over the following week, but the wide dispersion — especially the negative five-day reaction in May 2026 — shows that post-earnings price behavior is not mechanical.

For a deeper dive into how institutional analysts are weighting BD’s valuation, upcoming Waters transaction and earnings setup, look at the full institutional verdict on the ticker page.